Please login to the form below

Eloctate

This page shows the latest Eloctate news and features for those working in and with pharma, biotech and healthcare.

every few days, such as Shire’s Adynovate, Biogen’s Eloctate, Bayer’s Kovaltry and CSL Behring’s Afstyla, uptake hasn’t been as quick as hoped.

Roche’s Hemlibra first drug to top standard therapy in haemophilia A

well as Biogen’s Eloctate, Bayer’s Kovaltry and CSLBehring’s Afstyla.
Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

Bioverativ separated from Biogen last year to create a stand-alone haemophilia specialist with two marketed drugs - Eloctate (efmoroctocog alfa) and Alprolix (eftrenonacog alfa) which brought in sales estimated to be ... longer acting therapies such as
New data could unlock bigger market for Roche’s Hemlibra

Haemophilia A treatment is being transformed by a series of long-acting Factor VIII products such as Biogen’s Eloctate, Shire’s Adynovate, Bayer’s Kovaltry and CSLBehring’s Afstyla, which
Biogen spin-out makes first acquisition

Eloctate (efmoroctocog alfa) and Aprolix (eftrenonacog alfa).
Biogen completes haemophilia business separation

haemophilia A and B drugs, Eloctate (efmoroctocog alfa) and Aprolix (eftrenonacog alfa). ... The biotech was a latecomer to the $10bn haemophilia sector, but quickly gained ground with long-acting, low-dose therapies Eloctate and Aprolix, which

More from news
Approximately 3 fully matching, plus 21 partially matching documents found.

Deal Watch January 2018

Paying $105 per share in cash (64% premium over Bioverativ’s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as ... During 2016 Eloctate and Alprolix generated

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Add my company

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....